Grant of Options

RNS Number : 0763J

OptiBiotix Health PLC

31 March 2015

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

Grant of Options

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that it has today granted options to subscribe for, in aggregate, 1,717,544 ordinary shares of 2p each to two directors and one employee, pursuant to the terms of the Company's share option scheme.

The table below shows the details of the options granted to directors:

Director	Number of options granted	Exercise Price
Jim Laird	1,000,000	27.6p
Gareth Barker	358,772	20.0p

All of these options vest upon certain performance criteria being met and lapse on the tenth anniversary of the agreements. 

Following the grant of options, the total number of options outstanding over ordinary shares is 10,328,037, equivalent to 14.2% of the Company's existing issued share capital. 

For further information:

OptiBiotix Health plc	www.optibiotix.com
Stephen O'Hara, Chief Executive	Contact via Walbrook below
Cairn Financial Advisers LLP	Tel: [phone]
Liam Murray / Avi Robinson
Hybridan LLP (Joint Broker) Claire Louise Noyce	Tel: [phone]
Peterhouse Corporate Finance Ltd (Joint Broker)	Tel: [phone]
Lucy Williams / Duncan Vasey
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Anna Dunphy	Mob: [phone]
Mike Wort	Mob: [phone]

About OptiBiotix - www.optibiotix.com

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

END

 

 

MSCSDSFMFFISEDD